By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
latest_posts
- 1
Figure out How to Acquire Rewarding Open Record Rewards - 2Haunting Giant Squid Surfaces in Japan and Devours Its Prey (Video)
- 3Wisconsin archaeologists identify 16 ancient canoes in a prehistoric lake 'parking lot'
- 4The most effective method to Pick the Right Material Organization: Fundamental Tips
- 5Reveal Less popular Authentic Realities You Didn't Learn in School
- From record warming to rusting rivers, 2025 Arctic Report Card shows a region transforming faster than expected
- NASA says Maven spacecraft that was orbiting Mars has gone silent
- Parents speak out as 4-year-old fights button battery injury in intensive care unit
- Protest inspired by 'Gen Z' movement draws few young people in Mexico and many government critics
- Step by step instructions to Guarantee Your Fender bender Legal counselor has Areas of strength for a Record
- Hundreds of Intact Dinosaur Eggs Emerge From 72-Million-Year Time Capsule
- 6 Objections for an Ocean side Wedding
- Farmers call for French blockades over cow disease cull
- Dark matter may be made of pieces of giant, exotic objects — and astronomers think they know how to look for them
